相关实验视频

Updated: Sep 8, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

FLT1作为缺血性中风的保护因素:来自现实世界药物监测和遗传证据的见解

Haohao Chen^1,2, Jinhua Yang², Zihao Li³

¹Department of Pharmacy, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.

Translational stroke research

|July 18, 2025

概括

这项研究确定FLT1作为潜在的保护因子,防止缺血性中风. 结合药物监测和遗传数据,它为中风治疗提供了一个有希望的新目标.

科学领域:

生物医学研究的研究.
药理学药理学是指药理学的学科.
遗传学遗传学是一个

背景情况:

缺血性中风是全球死亡和残疾的主要原因.
治疗缺血性中风的有效分子标是有限的.
迫切需要新的治疗策略.

研究的目的:

发现和验证缺血性中风的新型分子标.
将现实世界的药监数据与分子和遗传证据相结合.
为了确定缺血性中风的潜在治疗干预措施.

主要方法:

使用一个分步的分析管道,结合FDA不良事件报告系统 (FAERS) 数据,DrugBank和门德尔随机化 (MR).
对FAERS数据进行了不成比例分析,以确定与缺血性中风信号相关的药物.
雇员MR使用英国生物银行制药蛋白质组项目 (UKB PPP) 蛋白质组数据和GIGASTROKE/FinnGen GWAS数据进行因果推断.

主要成果:

确定FLT1是MR分析和FAERS相关药物之间唯一重叠的蛋白质标.
在发现和验证数据集中证明了血FLT1水平和缺血性中风风险之间存在显著的反向因果关系.
在MAPK和PI3K-Akt等途径中显示FLT1丰富,这对于中风相关的分子过程至关重要.

结论:

通过三角化方法,FLT1被确定为潜在的预防缺血性中风的保护因素.
这些发现提供了对中风病原体的机制性见解.
FLT1代表了新型缺血性中风干预的有前途的治疗标.

关键词:

公平的人是公平的.FLT1 FLT1 的意思是 FLT1.在GWAS中,GWAS就是GWAS.缺血性中风是因为缺血性中风.门德尔的随机化药物监督药物监督药物监督

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

相关概念视频

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...